Comparative Effects of Felodipine, Nitrendipine and Nifedipine in Healthy Subjects: Concentration-effect Relationships of Racemic Drugs and Enantiomers

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1993 Jan 1

PMID 8453956

Citations 5

Authors

P A Soons

A F Cohen

D D Breimer

Affiliations

Soon will be listed here.

Abstract

The effects of racemic (rac) felodipine, rac-nitrendipine and nifedipine (all 20 mg solution p.o.) on non-invasively measured blood pressure and heart rate were investigated in a randomised, double-blind, cross-over study in 12 normotensive, young, healthy males. Compared to baseline values, heart rate increased more after rac-felodipine treatment (+47% at maximum) than rac-nitrendipine (+40%) and nifedipine (+38%); only small and variable changes in blood pressure were observed with any of the drugs. The baseline-corrected area under the heart rate-time curve up to 4 h after the administration of rac-felodipine was 197% and 180% larger than after nifedipine and rac-nitrendipine treatment, respectively. The effects on heart rate could be fitted individually to a sigmoidal Emax-model without hysteresis for all drugs under investigation. The relative potencies of the unbound drugs for their indirect effects on heart rate were 1:7:43 for nifedipine, rac-nitrendipine and rac-felodipine, respectively. The active (S)-enantiomers of felodipine and nitrendipine appeared to be 9- and 60-times as potent as nifedipine in this respect, assuming no (inter)activity of the (R)-enantiomers. Individual and mean changes in blood pressure were small, they were not related to plasma concentrations, and did not differ between treatments.

Citing Articles

Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods.

Coelho M, Fernandes C, Remiao F, Tiritan M Molecules. 2021; 26(11).

PMID: 34070985 PMC: 8197169. DOI: 10.3390/molecules26113113.

1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Cataldi M, Bruno F Transl Med UniSa. 2013; 4:12-26.

PMID: 23905059 PMC: 3728803.

Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.

ERICSSON H, Fakt C, Jolin-Mellgard A, NORDLANDER M, Sohtell L, Sunzel M Br J Clin Pharmacol. 1999; 47(5):531-8.

PMID: 10336577 PMC: 2014189. DOI: 10.1046/j.1365-2125.1999.00933.x.

Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Iwaoka T, Inotsume N, Inoue J, Naomi S, Okamoto Y, Higuchi S Eur J Clin Pharmacol. 1995; 48(5):345-9.

PMID: 8641321 DOI: 10.1007/BF00194949.

Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Soons P, Grib C, Breimer D, Kirch W Clin Pharmacokinet. 1992; 23(3):238-48.

PMID: 1355019 DOI: 10.2165/00003088-199223030-00006.

References

Edgar B, Regardh C, Attman P, Aurell M, Herlitz H, Johnsson G . Pharmacokinetics of felodipine in patients with impaired renal function. Br J Clin Pharmacol. 1989; 27(1):67-74. PMC: 1379706. DOI: 10.1111/j.1365-2125.1989.tb05336.x. View

Triggle D, Langs D, Janis R . Ca2+ channel ligands: structure-function relationships of the 1,4-dihydropyridines. Med Res Rev. 1989; 9(2):123-80. DOI: 10.1002/med.2610090203. View

Bellemann P, Schade A, Towart R . Dihydropyridine receptor in rat brain labeled with [3H]nimodipine. Proc Natl Acad Sci U S A. 1983; 80(8):2356-60. PMC: 393819. DOI: 10.1073/pnas.80.8.2356. View

FLECKENSTEIN A . Historical overview. The calcium channel of the heart. Ann N Y Acad Sci. 1988; 522:1-15. DOI: 10.1111/j.1749-6632.1988.tb33337.x. View

Blychert E, Hedner T, Dahlof C, Elmfeldt D . Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol. 1990; 15(3):428-35. DOI: 10.1097/00005344-199003000-00013. View

Eltze M, Boer R, Sanders K, Boss H, Ulrich W, Flockerzi D . Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists. Chirality. 1990; 2(4):233-40. DOI: 10.1002/chir.530020408. View

Kleinbloesem C, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer D . Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther. 1987; 41(1):26-30. DOI: 10.1038/clpt.1987.5. View

GODFRAIND T, Miller R, Wibo M . Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986; 38(4):321-416. View

Gutierrez L, Lesko L, Whipps R, Carliner N, Fisher M . Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. J Clin Pharmacol. 1986; 26(8):587-92. DOI: 10.1002/j.1552-4604.1986.tb02954.x. View

10.

Edgar B, Regardh C, Lundborg P, Romare S, Nyberg G, Ronn O . Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos. 1987; 8(3):235-48. DOI: 10.1002/bdd.2510080305. View

11.

Brisac A, Champeroux P, Lucet B, Laurent S, Schmitt H . Central and peripheral hypotensive effects of the optical isomers of nicardipine, a dihydropyridine calcium channel antagonist, in rats. Eur J Pharmacol. 1988; 146(1):171-4. DOI: 10.1016/0014-2999(88)90499-2. View

12.

Towart R, Wehinger E, Meyer H, Kazda S . The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung. 1982; 32(4):338-46. View

13.

Banzet O, Colin J, Thibonnier M, Singlas E, Alexandre J, Corvol P . Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol. 1983; 24(2):145-50. DOI: 10.1007/BF00613808. View

14.

Traube M, Hongo M, McAllister Jr R, McCallum R . Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol. 1985; 25(2):125-9. DOI: 10.1002/j.1552-4604.1985.tb02812.x. View

15.

Briand V, Laurent S, Legrand M, Brisac A, Schmitt H . Central and peripheral cardiovascular effects of the enantiomers of the calcium antagonist PN 200-110. Eur J Pharmacol. 1988; 150(1-2):43-50. DOI: 10.1016/0014-2999(88)90748-0. View

16.

Andersson O, Bengtsson C, Elmfeldt D, Haglund K, Hedner T, Seideman P . Short-term effects of felodipine, a new dihydropyridine, in hypertension. Br J Clin Pharmacol. 1984; 17(3):257-63. PMC: 1463385. DOI: 10.1111/j.1365-2125.1984.tb02340.x. View

17.

Ohtsuka M, Yokota M, Kodama I, Yamada K, Shibata S . New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype. Gen Pharmacol. 1989; 20(5):539-56. DOI: 10.1016/0306-3623(89)90084-0. View

18.

Campbell D . The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology (Berl). 1990; 100(4):433-50. DOI: 10.1007/BF02243994. View

19.

Kleinbloesem C, van Brummelen P, van Harten J, Danhof M, Breimer D . Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther. 1985; 37(5):563-74. DOI: 10.1038/clpt.1985.89. View

20.

Dunselman P, Edgar B, Scaf A, Kuntze C, van Bruggen A, Lie K . Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure. J Cardiovasc Pharmacol. 1989; 14(3):438-43. DOI: 10.1097/00005344-198909000-00013. View